| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 33,480 | 2,640 | 2,760 | 0 | 0 |
| Sales Growth | +1,168.18% | -4.35% | unch | unch | unch |
| Net Income | -52,700 | -61,020 | -49,120 | -2,740 | -380 |
| Net Income Growth | +13.63% | -24.23% | -1,692.70% | -621.05% | -123.53% |
Orchestra Biomed Hldgs Inc (OBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Orchestra BioMed Inc. is a biomedical company accelerating high-impact technologies to patients. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy(TM)for the treatment of hypertension and Virtue(R) Sirolimus AngioInfusion(TM) Balloon for the treatment of atherosclerotic artery disease. Orchestra BioMed Inc., formerly known as Health Sciences Acquisitions Corporation 2, is based in NEW HOPE, Pa.
Fiscal Year End Date: 12/31